Features of the course and the prognosis in patients with multiple myeloma depending on the renal involvement

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim: comparative analysis of factors influencing the course and prognosis of multiple myeloma, depending on the involvement of the kidneys.

Material and methods. Clinical and laboratory parameters of 100 patients with multiple myeloma were studied: 50 patients with renal involvement (I group) and 50 patients without it (II group). Demographic, constitutional indicators, and treatment regimens were comparable in both groups.

Results. In patients with kidney damage, the diagnosis was established on average after 12,8±2,9 months from the onset of complaints, and in patients without kidney damage – 7,9±1,2 months (t=1,5; p>0,05). Patients with multiple myeloma and kidney damage had significantly lower hemoglobin levels and more often destructive skeletal lesions. By the myelograms, the average percentage of plasma cells in patients with kidney damage is higher than in patients without kidney damage (39,9±2,7% vs 27,6±3,1%, t=3; р<0,01). 13 (26%) patients of the first group required hemodialysis sessions, and in 9 (~70%) of them dialysis treatment was started at the time of diagnosis. In 74% of patients with kidney damage, renal function improved during chemotherapy.

Conclusion. Timely diagnosis of MM will avoid severe kidney damage, promote better renal response and improve the prognosis of the disease.

Full Text

Restricted Access

About the authors

Zarine E. Grigoryan

Stavropol State Medical University; ANMO «Nephrological center»

Author for correspondence.
Email: Grigoryan-Z@yandex.ru
ORCID iD: 0009-0002-1195-9180

Cand.Sci. (Med), Assistant at the Department of Faculty Therapy of the Stavropol State Medical University; nephrologist at ANMO “Nephrological center”

Russian Federation, Stavropol; Stavropol

Yana M. Marchenko

Stavropol State Medical University; Stavropol regional clinical oncological center

Email: Yandex2005@mail.ru

Cand. Sci. (Med), Assistant at the Department of Hospital Therapy of the Stavropol State Medical University; hematologist at Stavropol regional clinical oncological center

Russian Federation, Stavropol; Stavropol

Milena V. Khachatryan

Stavropol State Medical University

Email: kha4atryan.milena@yandex.ru

Student 

Russian Federation, Stavropol

References

  1. Клинические рекомендации «Множественная миелома», 2022 г. [Clinical guidelines “Multiple myeloma”, 2022 (In Russ.)].
  2. Bradwell A.R. MB ChB, FRCP, FRCPath Serum Free Light Chain Analysis (plus Hevylite), 6th Edition, 2010.
  3. Yadav P., Cook M., Cockwell P. Current trends of renal impairment in multiple myeloma. Kidney Dis. (Basel, Switzerland) 2016;1(4):241–57. doi: 10.1159/000442511.
  4. Рехтина И.Г., Менделеева Л.П., Варламова Е.Ю. Бирюкова Л.С. Сравнение эффективности бортезомиб-содержащих программ в достижении раннего гематологического и почечного ответа у больных миеломной нефропатией с диализзависимой почечной недостаточностью. Гематология и трансфузиология. 2015;60(4):4–7. [Rekhtina I.G., Mendeleeva L.P., Varlamova E.Yu. Biryukova L.S. Comparison of the efficiency of bortezomib-based protocols in induction of an early hematological and renal response in myeloma nephropathy patients with hemodialysis-dependent renal failure. Hematol. Transfusiol. 2015;60(4):4–7 (In Russ.)].
  5. Haynes R.J., Read S., Collins G.P., et al. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: A 20-year experience from a single center. Nephrol. Dial. Transplant. 2010;25(2):419–26.
  6. Chan D.T., Craig K., Donovan K., Phillips A. Myeloma renal disease: Presentation and outcome. Nephron. Clin. Pract. 2006;104(3):126–31.
  7. Cancarini G., Terlizzi V., Garatti A., et al. Supportive treatment for cast nephropathy in patients with multiple myeloma; a pilot study. J. Nephropharmacol. 2021;10(2):e21. doi: 10.34172/npj.2021.20.
  8. Knudsen L.M., Hippe E., Hjorth M., et al. Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur. J. Haematol. 1994;53(4):207–12. Doi: 10.1111/ j.1600-0609.1994.tb00190.x. PMID: 7957804.
  9. Писаревская О.Н., Котельникова А.Н., Казаков С.П. и др. Роль парапротеинов в поражении почек у пациентов с лимфопролиферативными заболеваниями. Онкогематология. 2019;14(3):60–8. [Pysarevskaya O.N., Kotelnikova A.N., Kazakov S.P., et al. The role of paraproteins in kidney damage in patients with lymphoproliferative diseases. Oncohematol. 2019;14(3):60–8 (In Russ.)].
  10. Бессмельцев С.С. Множественная миелома (Патогенез, клиника, диагностика, дифференциальный диагноз). Часть 1. Клиническая онкогематология. 2013;3. [Bessmeltsev S.S. Multiple myeloma (Pathogenesis, clinical picture, diagnosis, differential diagnosis). Part 1. Clin. Oncohematol. 2013;3 (In Russ.)].
  11. Сараева Н.О., Горохова Л.А., Хороших О.В. и др. Механизмы развития анемии у больных множественной миеломой. Сибирский медицинский журнал. 2006;7:28–30. [Saraeva N.O., Gorokhova L.A., Khoroshikh O.V., et al. The mechanisms of anemia development in the patients with multiple myeloma. Siber. Med. J. 2006;7:28–30 (In Russ.)].
  12. Rainone F., Raza S.M.A, Ritchie J., et al. Associations Between Initial Presentation of Multiple Myeloma and Renal Function: the Experience of Two European Centers. J. Hematol. 2016;5(1):8–16.
  13. Hogan J.J., Alexander M.P., Leung N. Dysproteinemia and the kidney: Core Curr. 2019. Am. J. Kidney Dis. 2019;74(6):822–36.
  14. Wu C.K., Yang A.H., Lai H.C., Lin B.S. Combined proximal tubulopathy, crystal-storing histiocytosis, and cast nephropathy in a patient with light chain multiple myeloma. BMC. Nephrol. 2017;18(1):170.
  15. Li J., Zhou D Bin, Jiao L., et al. Bortezomib and dexa-methasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clin. Lymph. Myel. 2009. doi: 10.3816/CLM.2009. n.077.
  16. Ludwig H., Rauch E., Kuehr T., et al. Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase I study. Haematol. 2015;100(3):385–91. Doi: 10.3324/ hae-matol.2014.115204.
  17. Dimopoulos M.A., Roussou M., Gavriatopoulou M., et al. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am. J. Hematol. 2016;91(5):499–502. doi: 10.1002/ajh.24335.
  18. Рехтина И.Г., Менделеева Л.П., Бирюкова Л.С. Диализзависимая почечная недостаточность у больных множественной миеломой: факторы обратимости. Тер. архив. 2015,7:72–6. [Rekhtina I.G., Mendeleeva I.P., Birinkova L.S. Dialysis-de-pendent renal failure in patients with multiple myeloma: Reversibility factors. Тher. Arch. 2015,7:72–6 (In Russ.)].
  19. Chanan-Khan A.A., Kaufman J.L., Mehta J., et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109(6):2604–606. doi: 10.1182/blood-2006-09-046409.
  20. Choi T., Ahn W., Shin D.W., et al. Association between Kidney Function, Proteinuria and the Risk of Multiple Myeloma: A Population-Based Retrospective Cohort Study in South Korea. Cancer Res. Treat. 2022;54(3):926–36. doi: 10.4143/crt.2021.951. [Epub 2021 Sep 27. PMID: 34583456; PMCID: PMC9296938].
  21. Рехтина И.Г., Казарина Е.В., Столяревич Е.С. и др. Прогностическое значение фиброза интерстиция в нефробиоптате в обратимости острого почечного повреждения при цилиндровой нефропатии у пациентов с множественной миеломой. Нефрология и диализ. 2019;21(3):312–19. [Rekhtina I.G., Kazarina E.V., Stolyarevich E.S., et al. Prognostic value of interstitial fibrosis in nephrobiopsy specimen in the reversibility of acute kidney injury in cylinder nephropathy in patients with multiple myeloma. Nephrol. Dial. 2019;21(3):312–19 (In Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. Stages of CKD in patients with kidney damage

Download (50KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies